Bristol-Myers Squibb signs $15.2 billion licensing deal with Jiangsu Hengrui Pharmaceuticals
Here's what it means for you.
This strategic partnership could reshape the pharmaceutical landscape by enhancing drug development capabilities.
What happened
Bristol-Myers Squibb signed a licensing deal with Hengrui Pharmaceuticals worth up to $15.2 billion.
The Context
- The deal includes 13 early-stage drug programs.
- None of the drugs have yet entered human clinical trials.
- This partnership comes as Bristol-Myers faces challenges from a patent cliff.
Takeaway
This collaboration may enhance Bristol-Myers' pipeline and mitigate risks associated with upcoming patent expirations.
This article was generated by AI from 4 verified sources and reviewed by A47 editorial systems.
Opinionated AI coverage for general audiences.
"TNW’s AI vertical covering tools, ethics, and trends."
— A47 Editor
BMS just signed a $15.2 billion drug deal with China’s biggest pharma company. The patent cliff left it no choice.
Bristol Myers Squibb (BMS) has entered into a significant agreement with Jiangsu Hengrui Medicine, China's largest pharmaceutical company, valued at up to $15.2 billion. This deal encompasses 13 early-stage drug programs focused on oncology, hematolo...
Brokerage upgrades/downgrades, price-target changes, and fresh coverage that move single names and sectors.
"Handy for tracking sentiment shifts from the sell side and consensus drift."
— A47 Editor
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal
BMO has reiterated its stock rating for Bristol-Myers Squibb in light of the recent deal with Hengrui, signaling confidence in the pharmaceutical company's strategic direction. This decision reflects BMO's assessment of Bristol-Myers Squibb's market ...
Global markets, investing, and macroeconomics from a premier financial newsroom.
"Bloomberg is respected for in-depth financial reporting and data-driven analysis."
— A47 Editor
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui
Bristol-Myers Squibb Co. has entered into a collaboration and licensing agreement with Jiangsu Hengrui Pharmaceuticals Co., potentially worth up to $15.2 billion. This strategic partnership aims to utilize China's efficiency in early drug development...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up
U.S. pharmaceutical company Bristol-Myers Squibb has entered into a partnership and licensing agreement with Chinese drugmaker Hengrui Pharma, a deal valued at over $15 billion. This collaboration marks a significant step in the global pharmaceutical...